Amgen faces EU withdrawal of Tavneos (AMGN:NASDAQ)

Amgen faces EU withdrawal of Tavneos (AMGN:NASDAQ)

Amgen (AMGN) stock is in focus as an expert panel of the European Medicines Agency recommends withdrawal of the company's rare-disease drug, Tavneos. Read more here.

EU regulators recommend revoking the marketing authorization for Amgen’s Tavneos

The European Medicines Agency has proposed revoking the marketing authorization for Amgen’s controversial rare disease drug Tavneos citing “incorrect and misleading” clinical data. The future of Amgen’s Tavneos has been in turmoil after being linked ...

Data Integrity Questions Lead Europe to Back Tavneos’ Withdrawal

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.